Pharmaceutical News

RSS

A discreet option for pain relief in the workplace

Employers say that back pain-related problems account for over 100 million lost workdays a year. In a cutthroat economy with unemployment at a record high, this is especially disconcerting news. Employees cannot afford to risk losing their jobs to other candidates while stuck home in bed recuperating. With 80% of Americans experiencing back pain in their lifetime, back issues have serious implications on job security and can negatively affect even the most dedicated employee’s performance abilities and job attendance.

12 Nov 2009

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (an infoGROUP company) (NASDAQ: IUSA) will present findings of the company’s recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week. The hearing will address the issue of fulfilling requirements for fair balance and risk disclosure in internet and social media promotions. The ORC Guideline study examined consumer habits in researching information about pharmaceutical products online.

12 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

IACC to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research

Autism Speaks is encouraged by yesterday's decision of the Interagency Autism Coordinating Committee (IACC) to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research. The new language, approved unanimously, calls for studies to determine if there are sub-populations that are more susceptible to environmental exposures such as immune challenges related to naturally occurring infections, vaccines or underlying immune problems.

12 Nov 2009

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Investors are betting on upcoming medical study results of BioElectronics, says BioMedReports

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that investors are betting that BioElectronics' (PINKSHEETS: BIEL) upcoming medical study results will be significant.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children

CSL Biotherapies, a subsidiary of CSL Limited, one of the world’s leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.

12 Nov 2009

54% of Americans are inconsistent in taking prescriptions, reveals survey

A new survey finds that 54 percent of Americans say they do not consistently take prescriptions as instructed even though 87 percent believe prescription medicines are important to their health – pointing to a growing public health problem.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Some benefits from prescription drug DTCA, but significant risks remain

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.

12 Nov 2009

FDA regulatory clearance for Kensey Nash's ECM product

Kensey Nash Corporation, a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration.

12 Nov 2009

CVS Caremark's medication adherence program for people with diabetes has positive impact

CVS Caremark said the company's comprehensive adherence program for people with diabetes positively impacts medication adherence for both new and continuing patients. A review of data tracking the program found that 75.6 percent of patients continuing on a diabetes therapy who participated in the adherence program maintained optimal adherence to their prescribed therapy vs. 61.2 percent in the control group.

12 Nov 2009

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. Those hard-to-treat diseases include malaria, tuberculosis, dengue fever, and other conditions. That's the topic of the cover story scheduled for the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

12 Nov 2009

CVS settles with NY over expired product sales; NC gets high-risk pool payment help

New York Attorney General Andrew Cuomo announced Tuesday that CVS, the drug story chain, has agreed to pay $875,000 to settle charges that it sold products years after their expiration dates, Reuters reports. The out-dated products, sold at 142 different stores, included "over-the-counter drugs, baby formula, eggs and milk," and in some cases items were sold more than two years after expiring (Stempel, 11/10).

11 Nov 2009

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

11 Nov 2009

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

11 Nov 2009

Cholesterol-lowering drugs associated with reduced risk of gallstone disease

Use of the cholesterol-lowering drugs statins for more than a year is associated with a reduced risk of having gallstones requiring surgery, according to a study in the November 11 issue of JAMA.

11 Nov 2009

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

11 Nov 2009

Pharmaceutical News

A discreet option for pain relief in the workplace

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

IACC to include vaccine research studies in the objectives of the updated Strategic Plan for Autism Research

Canadian researchers organize clinical trials to find new treatments for H1N1 infection

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Investors are betting on upcoming medical study results of BioElectronics, says BioMedReports

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children

54% of Americans are inconsistent in taking prescriptions, reveals survey

Nuvo Research announces new licensing agreement for Oxoferin

Some benefits from prescription drug DTCA, but significant risks remain

FDA regulatory clearance for Kensey Nash's ECM product

CVS Caremark's medication adherence program for people with diabetes has positive impact

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

CVS settles with NY over expired product sales; NC gets high-risk pool payment help

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Cholesterol-lowering drugs associated with reduced risk of gallstone disease

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News